Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-02-20
2004-08-31
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S045000, C514S046000, C514S047000, C514S048000, C514S049000, C514S050000, C514S051000, C536S028100, C536S028200, C536S028300, C536S028400, C536S028600, C548S952000
Reexamination Certificate
active
06784161
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogues.
BACKGROUND OF THE INVENTION
Hepatitis is a disease occurring throughout the world. It is generally of viral nature, although there are other causes known. Viral hepatitis is by far the most common form of hepatitis. Nearly 750,000 Americans are affected by hepatitis each year, and out of those, more than 150,000 are infected with the hepatitis C virus (HCV).
HCV is a positive-stranded RNA virus belonging to the Flaviviridae family and has closest relationship to the pestiviruses that include hog cholera virus and bovine viral diarrhea virus (BVDV). HCV is believed to replicate through the production of a complementary negative-strand RNA template. Due to the lack of an efficient culture replication system for the virus, HCV particles were isolated from pooled human plasma and shown, by electron microscopy, to have a diameter of about 50-60 nm. The HCV genome is a single-stranded, positive-sense RNA of about 9,600 bp coding for a polyprotein of 3009-3030 amino-acids, which is cleaved co- and post-translationally by cellular and two viral proteinases into mature viral proteins (core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B). It is believed that the structural proteins, E1 and E2, the major glycoproteins are embedded into a viral lipid envelop and form stable heterodimers. It is also believed that the structural core protein interacts with the viral RNA genome to form the nucleocapsid. The nonstructural proteins designated NS2 to NS5 include proteins with enzymatic functions involved in virus replication and protein processing including a polymerase, protease and helicase.
The main source of contamination with HCV is blood. The magnitude of the HCV infection as a health problem is illustrated by the prevalence among high-risk groups. For example, 60% to 90% of hemophiliacs and more than 80% of intravenous drug abusers in western countries are chronically infected with HCV. For intravenous drug abusers, the prevalence varies from about 28% to 70% depending on the population studied. The proportion of new HCV infections associated with post-transfusion has been markedly reduced lately due to advances in diagnostic tools used to screen blood donors.
The only treatment currently available for HCV infection is interferon-&agr; (IFN-&agr;). However, according to different clinical studies, only 70% of treated patients normalize alanine aminotransferase (ALT) levels in the serum and after discontinuation of IFN, 35% to 45% of these responders relapse. In general, only 20% to 25% of patients have long-term responses to IFN. Clinical studies have shown that combination treatment with IFN and ribavirin (RIBA) results in a superior clinical response than IFN alone. Different 30 genotypes of HCV respond differently to IFN therapy, genotype 1b is more resistant to IFN therapy than type 2 and 3.
There is therefore a great need for the further development of anti-viral agents.
SUMMARY OF THE INVENTION
The present invention relates to a method for the treatment or prevention of Flavivirus infections in a host comprising administering a therapeutically effective amount of a compound having the formula I or a pharmaceutically acceptable salt thereof:
wherein
B is chosen from a purine, a pyrimidine or an analogue thereof;
Ra is chosen from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C
1-6
alkyl, C
2-6
alkenyl, C
2-6
alkynyl, C
6-10
aryl, and
wherein each Rc are independently chosen from H, C
1-6
alkyl, C
2-6
alkenyl, C
2-6
alkynyl, C
6-10
aryl and an hydroxy protecting group; and
Z is halogen or ORb, wherein Rb is chosen from of H, C
1-6
alkyl, C
2-6
alkenyl, C
2-6
alkynyl, C
1-6
acyl, or an hydroxy protecting group
D
1
and D
2
are independently selected from N
3
, F, or H , D
1
and D
2
can also be joined to be chosen from C
3
-cycloalkyl, —═CH
2
, or —═CF
2
, and
wherein said compound is in the form of a single enantiomer or a mixture thereof including racemic mixtures;
with the proviso that when B is adenine, Z is ORb, D
1
is H, D
2
is H and Rb is H, Ra is not triphosphate or H.
In another aspect, there is provided a pharmaceutical formulation comprising the compounds of the invention in combination with a pharmaceutically acceptable carrier or excipient.
Still another aspect, there is provided a method for treating or preventing a viral infection in a host comprising administering a combination comprising at least one compound according to formula I and at least one further therapeutic agent.
In another aspect of the invention is the use of a compound according to formula I, for the preparation of a medicament for treating or preventing a viral infections in a host.
REFERENCES:
patent: 4963662 (1990-10-01), Matthes et al.
patent: 5506215 (1996-04-01), Johansson et al.
patent: 5705522 (1998-01-01), Hamedi-Sangsari et al.
patent: 6110901 (2000-08-01), Gluzman
patent: 0322384 (1996-03-01), None
patent: 1046648 (2000-10-01), None
patent: WO 94/26761 (1994-11-01), None
patent: WO 98/18324 (1998-05-01), None
patent: WO 99/43691 (1999-09-01), None
patent: WO 00/50064 (2000-08-01), None
patent: WO 00/62799 (2000-10-01), None
patent: WO 02/18404 (2002-03-01), None
Mikhailopulo et al. J. Med. Chem. (1991), vol. 34, pp. 2195-2202.*
Brillanti et al. Ital. J. Gastroenterol Hepatol (1999), vol. 31, pp. 130-134.*
Tai Shun et al., Synthesis and Anticancer Activity of Various 3′-Deoxy Pyrimidine Nucleoside Analogues and Crystal Structure of 1-(3-Deoxy-b-D-threo-pentofuranosyl) cytosine.
Mineo Saneyoshi et al., Synthetic Nucleosides and Nucleotides. XXXV. Synthesis and Biological Evaluations of 5-Fluoropyrimidine Nucleosides and Nucleotides of 3-Deoxy-&bgr;-D-ribofuranose and Related Compounds.
Janos Ludwig and Fritz Eckstein, “Rapid and Efficient Synthesis of Nucleoside 5′-O-(1-Thiotriphosphates), 5′-Triphosphates and 2′,3′-Cyclophosphorothioates Using 2-Chloro-4H-1,3,2-benzodioxaphosphorin-4-one”, J. Org. Chem. 1989, 54, 631-635.
Stephen Hanessian and Pierre Lavellée, “The Preparation and Synthetic Utility of tert-Butyldiphenylsilyl Ethers”, Can. J. Chem. 1975, 53(19), 2975-2977.
Stephen H. Kawai et al., “Synthesis of Branched-China And Bicyclic Thiosugar Nucleosides” from Nucleosides Nucleotides, edited by Leroy B. Towsend, 1988 Plenum Press Volumes 1 and 2, 1990, 9(8), 1045-1060.
Krzystof W. Pankiewicz et al., J. Org. Chem. 1992, 57, 7315-7321, Synthesis of 2′-&bgr;-Fluoro-and 3′-&agr;-Fluoro-Substituted Guanine Nucleosides. Effects of Sugar Conformational Shifts on Nucleophilic Displacement of the 2′-Hydroxy and 3′-Hydroxy Group with DAST.
Igor A. Mikhailopulo et al., J. Med. Chem. 1991, 34, 2195-2202, Synthesis and Antiviral and Cytostatic Properties of 3′-Deoxy-3′-Deoxy-3′-fluoro-and 2′-Azido-3′-fluoro-2′,3′-dideoxy-D-ribofuranosides of Natural Heterocyclic Bases.
Frédéric Puesch et al., Chem. Commun. 1989, (14), 955-957, Synthesis of 9-(3-Deoxy-3-fluoro-&bgr;-D-ribofuranosylguanine, a New Potent Antiviral Agent.
Van Aerschot et al., Antiviral Research, 12, 1989, 133-150, Synthesis and Antiviral Activity Evaluation of 3′-fluoro-3′-deoxyribonucleosides: Broad-Spectrum Antiviral Activity of 3′-fluoro-3′-deoxyadenosine.
Igor A. Mikhailopulo et al., FEBS Lett. 1989, 250(2), 139-141, 3′-Fluoro-3′-deoxyribonucleoside 5′-triphosphates: Synthesis and Use as Terminators of RNA Biosynthesis.
Hemant K. Misra et al., J. Heterocycl. Chem., May-Jun. 1984; 21(3), 773-775, Reaction of 1-(2,-3′-Epoxy-&bgr;-D-lyxofuranosyl)uracil with Hydrogen Fluoride. The Unexpected Formation of 1-(3′-Fluoro-3′-deoxy-&bgr;-ribofuranosyluracil.
G. Kowollik et al., J. Carbohydr. Nucleosides, Nucleotides, 1975, 2(3), 191-195, Nucleosides of Fluorocarbohydrates, XIII Synthesis of 3′-deoxy′3′-fluorouridine.
Tokumi Maruyama et al., Nucleic Acids Symp. Ser
Cheng Yun-Xing
Ismaili Hicham Moulay Alaoui
Lavallée Jean-François
Siddiqui Arshad
Storer Richard
Bio-Chem Pharma Inc.
Lewis Patrick T
Millen White Zelano & Branigan
LandOfFree
Method for the treatment or prevention of flavivirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment or prevention of flavivirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment or prevention of flavivirus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3344900